News 23 ET - News Release
Mr. W. Clark Kent reports
RELAY MEDICAL AND GLOW LIFETECH REPORT ON SUCCESSFUL PHASE II CLINICAL RESULTS FOR COVID-19 TREATMENT CANDIDATE BASED ON ITS MYCELL TECHNOLOGY
Relay Medical Corp. and Glow LifeTech Ltd., a private company in which Relay holds a significant equity interest, have provided an update on developments related to Glow's MyCell technology.
Glow LifeTech partner Swiss Pharmacan AG, and MGC Pharma have announced the full results of its phase two double-blind, placebo-controlled clinical trial for anti-inflammatory treatment ArtemiC, powered by MyCell Technology, on persons diagnosed with COVID-19, has successfully met all the phase two primary and secondary end points and demonstrated to improve the clinical recovery of COVID-19 patients.
MGC has completed its phase two randomized controlled clinical trial on ArtemiC involving 50 patients and the results show ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the placebo group. The results deliver a full safety and efficacy profile, demonstrating to improve and expedite the clinical recovery in moderate COVID-19 patients, with no drug-related adverse events. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared with 23.4 per cent in the placebo group requiring further assistance.
ArtemiC is a natural anti-inflammatory formulation by MGC Pharma, which is powered by Mycell technology, the same delivery system technology that Glow LifeTech has the exclusive North American (United States, Canada, Mexico) licence to manufacture, sell and market for cannabis and certain nutraceutical ingredients. The natural formulation, jointly developed by Glow partner Swiss PharmaCan, is based on four MyCell enhanced ingredients: Artemisinin, Curcumin, Vitamin C and Boswellia Serrata, which are well-known natural active ingredients with anti-inflammatory properties. The formulation is intended to suppress the cytokine storm and clinical deterioration to support the recovery of COVID-19 patients. Glow LifeTech owns the exclusive rights for the sale, manufacturing and distribution of MyCell curcumin in the United States, Canada and Mexico.
"These are very exciting results for Glow's MyCell technology and the ArtemiC formulation. We are pleased that our innovative MyCell technology is helping to power a natural formulation that shows promising ability to improve and expedite the recovery of COVID-19 patients. It demonstrates the long-term potential of MyCell technology to power next-generation natural health products with science-backed efficacy and safety," said Clark Kent, chief executive officer, Glow LifeTech.
MGC completed its trial on ArtemiC on 50 COVID-19 infected patients across three independent hospital sites in Israel. The trial met all the Food and Drug Administration requirements for a COVID-19 study. These results now open potential market opportunities for ArtemiC to a wide range of diseases related to cytokine storm such as influenza, autoimmune diseases, inflammatory gastrointestinal diseases and chemotherapy patients.
Following the successful phase two results, MGC plans to develop and commence a phase three clinical trial in the first half of 2021. The phase three trial is anticipated to be an international multicentre study to encompass a wide range of inflammatory indications for the use of ArtemiC as a treatment.
"Relay and Glow are critical partners of ours in commercializing MyCell Technology in North America and beyond. We look forward to building on our relationship as we roll out breakthrough innovations like ArtemiC. With Glow preparing to list on the CSE, they will positioned well to support our mission of bringing innovative health products to the market," said Michel Fassler, managing director, Swiss PharmaCan AG.
On Nov. 25, 2020, Glow Lifetech announced that it had received conditional approval to list its common shares on the Canadian Securities Exchange pursuant to an amalgamation transaction with Ateba Resources Inc. Glow's conditional approval to list its common shares on the CSE is subject to the completion of a financing raise of an additional $2.5-million and the completion of the amalgamation with Ateba.
Glow and Swiss PharmaCan have initiated a regulatory assessment to determine the best path forward for the commercialization of ArtemiC in North America.
About Relay Medical Corp.
Relay Medical is a medtech innovation company headquartered in Toronto, Canada, focused on the development of novel technologies in the diagnostics and artificial intelligence data science sectors.
We seek Safe Harbor.